TP53 and ovarian carcinoma: In addition, we confirmed that elevated levels of anti-TP53 autoantibodies can be detected in as many as 20–25% of patients with ovarian cancer and titers of anti-TP53 rise 8 months prior to CA125 and 22 months prior to diagnosis in patients where CA125 levels did not increase [18].